[CAS NO. 1058137-23-7] Lucitanib (E3810) hydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1058137-23-7]

Catalog

SLK-S7647

Brand

Selleck

CAS

1058137-23-7

DESCRIPTION [1058137-23-7]

Overview

MDL	MFCD20527751
Molecular Weight	479.96
Molecular Formula	C26H26ClN3O4
SMILES	O(C=1C2=C(C=C(OCC3(N)CC3)C(OC)=C2)N=CC1)C4=CC5=C(C=C4)C(C(NC)=O)=CC=C5

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.0835 mL	10.4175 mL	20.8351 mL
5 mM	0.4167 mL	2.0835 mL	4.1670 mL
10 mM	0.2084 mL	1.0418 mL	2.0835 mL
50 mM	0.0417 mL	0.2084 mL	0.4167 mL

Description

Lucitanib (E-3810, AL3810) hydrochloride is a dual inhibitor of and . Lucitanib hydrochloride (E-3810, AL3810) potently and selectively inhibits , , , and with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

Targets

VEGFR1 ^[1] (Cell-free assay)	VEGFR3 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR2 ^[1] (Cell-free assay)
7 nM	10 nM	17.5 nM	25 nM	82.5 nM

In vitro

In vitro Lucitanib (E3810) inhibits the VEGF- and bFGF-dependent proliferation and the signaling transduction pathways elicited by VEGF and bFGF ligands binding to their cognate receptors in HUVEC cells in the nanomolar range.

References

[1] Ezia Bello, et al. Cancer Res. 2011 Feb 15;71(4):1396-405.

Synonyms

1-Naphthalenecarboxamide, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-

6-[[7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide

Lucitanib

AL 3810

E 3810